Contents

Search

defibrotide (Defitelio)

Indications: - hepatic veno-occlusive disease Contraindications: - anticoagulation - fibrinolytic therapy Dosage: - 6.25 mg/kg IV q6 hours given as a 2-hour infusion for at least 21 days, & continued until hepatic veno-occlusive disease resolution or up to 60 days of treatment Adverse effects: - hypotension, diarrhea, vomiting, nausea, epistaxis Mechanism of action: - pro-fibrinolytic activity

General

hematologic agent

References

  1. FDA Approved Drugs. March 30, 2016 Defitelio (defibrotide sodium) http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm493278.htm